C4 Therapeutics, Inc. 8-K

What Happened C4 Therapeutics, Inc. (CCCC) filed a Form 8-K on June 11, 2026 to disclose a corporate presentation and additional clinical updates for cemsidomide, its next‑generation oral IKZF1/3 degrader. The company posted a corporate presentation to its investor site and published a poster and press release with further analysis from its fully enrolled Phase 1 trial of cemsidomide plus dexamethasone for relapsed/refractory multiple myeloma (RRMM), to be presented at the EHA 2026 Congress.

Key Details

• Date filed: June 11, 2026 (Form 8-K Items 7.01 and 8.01).
• Documents furnished/posted: corporate presentation (Exhibit 99.1), EHA poster (Exhibit 99.2), and press release (Exhibit 99.3).
• Drug & indication: cemsidomide, oral IKZF1/3 degrader, in combination with dexamethasone for RRMM.
• Trial status: further analysis from a fully enrolled Phase 1 trial; data to be presented at the European Hematology Association (EHA) 2026 Congress.

Why It Matters This 8-K alerts investors that C4 is publicly sharing new clinical data and investor materials on cemsidomide, which may inform the drug’s clinical progress and development timeline for RRMM. The filings themselves do not report financial results or regulatory decisions, but they provide updates on clinical evidence and upcoming scientific presentation that investors often watch for signs of program momentum.